Endometrial cancer care is increasingly shaped by molecular information, making biomarker testing an essential part of treatment planning for patients with advanced or recurrent disease. In this episode of Inside the Lab, host Dr. Ali Brown, CEO of the American Society for Clinical Pathology, speaks with Dr. Casey Cosgrove, a gynecologic oncologist at The Ohio State University, and Dr. Meg Dibbern, a breast and gynecologic pathologist at Emory University, about how biomarkers including MMR/MSI, POLE, p53, and HER2 can help define tumor biology, inform prognosis, and guide systemic treatment decisions. The guests explore how testing across immunohistochemistry, PCR, and next-generation sequencing fits into real-world laboratory workflows and how pathology and oncology teams can work together to ensure results are comprehensive, timely, and actionable. The discussion also considers the challenges of translating evolving clinical guidelines into practice and the importance of communication between the laboratory, clinicians, and patients as treatment options continue to expand. To claim credit for listening to this episode, please click here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related